In This Article:
As global markets navigate the initial policy shifts of the Trump administration, U.S. stocks have surged to record highs, buoyed by optimism around potential trade deals and AI investment initiatives. Amidst this backdrop of economic activity and investor sentiment, growth companies with high insider ownership are capturing attention for their robust earnings performance.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.2% |
| Duc Giang Chemicals Group (HOSE:DGC) | 31.4% | 25.7% |
| Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Laopu Gold (SEHK:6181) | 36.4% | 36.6% |
| Medley (TSE:4480) | 34.1% | 27.3% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 135% |
| HANA Micron (KOSDAQ:A067310) | 18.2% | 119.4% |
Let's uncover some gems from our specialized screener.
ID Logistics Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ID Logistics Group SA offers contract logistics services both in France and internationally, with a market capitalization of approximately €2.59 billion.
Operations: The company's revenue segment includes Transportation - Trucking, which generated €241.88 million.
Insider Ownership: 21.2%
Earnings Growth Forecast: 21.1% p.a.
ID Logistics Group showcases promising growth potential with earnings forecasted to increase by 21.1% annually, outpacing the French market's 12%. Despite a low future return on equity of 11%, the company's revenue is expected to grow at 11.3% per year, surpassing the market's 5.5%. However, interest payments are not well covered by earnings, which could pose financial challenges. The stock trades at a substantial discount compared to its estimated fair value.
ALTEOGEN
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩19.29 trillion.
Operations: The company generates revenue primarily from its biotechnology segment, amounting to ₩74.38 billion.
Insider Ownership: 25.9%
Earnings Growth Forecast: 140.6% p.a.
Alteogen is poised for significant growth, with revenue projected to increase by 84.2% annually, far outpacing the South Korean market's 9.2%. The company is expected to become profitable within three years and boasts a very high forecasted return on equity of 67.6%. Recent developments include an exclusive license agreement with Daiichi Sankyo for ALT-B4, potentially enhancing future revenue streams through milestone payments and royalties. Despite these positives, the stock remains highly volatile yet trades significantly below its fair value estimate.